Wuxi Biortus Biosciences Co. Ltd. (“Biortus”), a global leader in structural biology service for drug discovery, recently closed round A financing with US$15 million investment led by Bayland Capital, and the fund will be used to establish a global cryo-EM innovation center.
Microcrystal electron diffraction (MicroED) is a new crystal structure determination technique for small molecules. It obtains diffraction patterns of small molecule microcrystal from an electron microscope, and resolves the atomic-resolution structure (better than 1.0A) with the traditional crystallography approach. The emergence of MicroED technology has raised great interest within the pharmaceutical research and development community. This technology holds great prospects of identifying the crystal form of drug substance, determining the structure of a natural product, and analyzing impurity in CMC process.
Leucine-rich repeat kinase 2 (LRRK2) is implicated in the pathogenesis of Parkinson’s disease (PD), which is the second most common neurodegenerative movement disorder and affects 1–2% of all people above the age of 65. Unfortunately, there has been no effective cure for PD yet. LRRK2 is one of the most promising therapeutic targets for drug therapy in PD and several LRRK2 inhibitors are currently in clinical trials.